ATLANTA, April 8 /PRNewswire/ -- Extensive new data on rotigotine will be presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada between April 10th and 17th, 2010.
Oral presentations
Hogl B, Trenkwalder C, Garcia-Borreguero D, Kohnen R, Poewe W, Stiasny-Kolster K, Bauer L, Fichtner A, Schollmayer E, Oertel W for the SP710 study group
RECOVER: Effect of Rotigotine on Non-motor Symptoms in Subjects with Idiopathic Parkinson's Disease
The presentation will report on the effect of rotigotine on non-motor symptoms of Parkinson's disease, such as sleep, mood and cognition.
RECOVER: Effect of Rotigotine on Sleep Quality and Control of Early Morning Motor Function in Subjects with Idiopathic Parkinson's Disease
Kies B, Chaudhuri KR, Anderson T, Fine J, Hill DL, Rudzinska M, Surmann E, Whitesides J, Boroojerdi B, Trenkwalder C on behalf of the RECOVER Study Group
LeWitt P, Boroojerdi B, Poewe W, on behalf of the SP516 and SP715 study groups
Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease
The presentation will report on the long-term efficacy and tolerability of rotigotine in early stage Parkinson's disease.
Neupro(R) in Europe Important Safety Information
Neupro(R) is contraindicated in case of hypersensitivity to the active substance or to any of its excipients, and in case of magnetic resonance imaging (MRI) or cardioversion. Neupro(R) should be removed if the patient has to undergo MRI or cardioversion.
Neupro(R) has been associated with somnolence episodes of sudden sleep onset episodes. Patients treated with dopamine agonists including Neupro(R), have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality.
Neupro(R) contains sodium metabisulphite, a sulphite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain susceptible people.
Cases of cardiopulmonary fibrotic complications have been reported in some patients treated with ergot-derived dopaminergic agents. Neuroleptics given as antiemetic should not be given to patients taking dopamine agonists. Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur.
Caution is advised when treating patients with severe hepatic impairment or acute worsening of renal function, a dose reduction might be needed.
Neupro(R) should not be used during pregnancy. Breast-feeding should be discontinued.
Adverse drug reactions reported in more than 10% of Parkinson's patients treated with Neupro(R) are nausea, vomiting, application site reactions, somnolence, dizziness and headache.
All Neupro(R) supply should be stored in a refrigerator. There is no need for patients to transport Neupro(R) patches in special containers and they must not be stored in a freezer compartment.
About Neupro(R) in the U.S.
Neupro(R) is a registered trademark of the UCB Group of companies.
About UCB
UCB, Brussels, Belgium is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels .
UCB
